Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

In a bid to optimize its resources and maximize long-term growth potential SurModics Inc. (SRDX - Analyst Report) announced that it will trim its work-force by 6%. The move is expected to result in annual savings of approximately $0.9 million to $1.1 million.

Moreover, the organizational restructuring is expected to result in a one-time restructuring charge of approximately $0.5 million (2 cents per share) in the final quarter of fiscal 2013 (ending Sep 30, 2013) for SurModics.

SurModics’ two units, Quality, Regulatory and Clinical Affairs function and Medical Device Research and Development, will start reporting directly to CEO Gary Maharaj right away. These units were previously accountable to business segment leaders. The changes are likely to provide these units with the executive focus and alignment necessary to accomplish SurModics’ strategic objectives.

Moreover, Andy LaFrence, the Vice President of finance and chief financial officer at SurModics will also supervise the Operations and Information Systems operations going forward. LaFrence joined the company in Dec 2012. The presence of LaFrence is expected to be beneficial to SurModics since he is vastly experienced in finance and capital markets.

We note that this is not the first time that SurModics, a provider of surface modification and drug delivery technologies to the healthcare industry, has reorganized its business. In Aug 2011, the company trimmed its work-force by 9%. The company slashed its work force in 2010 as well.

We are positive on the steps taken by SurModics to increase efficiencies. Moreover, the company’s initiative to sell its Pharmaceutical unit to focus on its core business is also a prudent move.

SurModics currently carries a Zacks Rank #2 (Buy). Boston Scientific Corporation (BSX - Analyst Report) and Advaxis, Inc. (ADXS) are examples of equally attractive stocks operating in the same field as SurModics. Alere Inc. (ALR - Snapshot Report) appears to be more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.59 +6.17%
RAMBUS INC RMBS 12.42 +5.34%
BOFL HOLDING BOFI 85.31 +4.98%
NETFLIX INC NFLX 345.50 +4.25%
VIPSHOP HOLD VIPS 148.00 +3.84%